Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Open Access
- 26 March 2021
- journal article
- research article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 21 (5) , 535-543
Abstract
Introduction ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) demonstrated the efficacy and safety of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM). Model-based analyses from ATTR-ACT can examine predictor effects on dose–response/exposure–response relationships. Methods Parametric hazard distributions were developed for all-cause mortality and frequency of cardiovascular-related hospitalization. Time-to-event models were fitted to survival data, and repeated time-to-event models were fitted to hospitalization data. Disease-specific characteristics were assessed as baseline predictors of event hazards. Results There were 441 patients in this analysis. At month 30, 70.5% (tafamidis) and 57.1% (placebo) of patients were alive, with 154/441 deaths reported; 495 cardiovascular-related hospitalizations occurred. The cumulative risk of death was 42.1% (95% confidence interval [CI] 24.2–58.0) lower with tafamidis than with placebo, regardless of New York Heart Association (NYHA) class; significant predictors of decreased risk were genotype (wild-type), greater 6-Minute Walk Test (6MWT) distance, higher left ventricular ejection fraction (LVEF), and lower blood urea nitrogen (BUN) and N-terminal pro-B-type natriuretic peptide concentrations. The average cumulative risk of cardiovascular-related hospitalization up to 30 months was 40.8% (95% CI 31.0–49.7) lower with tafamidis in NYHA class I/II patients. Significant predictors of reduced risk were greater 6MWT distance, higher LVEF, and lower BUN and troponin I concentrations. Conclusions Tafamidis reduced cumulative mortality and hospitalization risk versus placebo in patients with ATTR-CM. Baseline predictors of outcome were consistent with the cardiovascular nature of the disease and suggested that earlier treatment may improve outcomes. Clinical Trials.gov Identifier NCT01994889 (date of registration: November 26, 2013).Keywords
Funding Information
- Pfizer
This publication has 21 references indexed in Scilit:
- Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin AmyloidosisNeurology and Therapy, 2016
- Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type TransthyretinCirculation, 2016
- Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathyJournal of Neurology, 2013
- Incidence, Diagnosis and Prognosis of Cardiac AmyloidosisKorean Circulation Journal, 2013
- Transthyretin (TTR) Cardiac AmyloidosisCirculation, 2012
- Tafamidis for transthyretin familial amyloid polyneuropathyNeurology, 2012
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProceedings of the National Academy of Sciences, 2012
- Familial amyloid polyneuropathyThe Lancet Neurology, 2011
- A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of OndansetronJournal of Pharmacokinetics and Biopharmaceutics, 1999
- Combining mortality and longitudinal measures in clinical trialsStatistics in Medicine, 1999